IMAB (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon, commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases.

The Company’s mission is to bring transformational medicines to patients around the world through innovation. IMAB’s innovative pipeline is driven by the Company’s Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnering deals. IMAB’s advanced and globally competitive pipeline is now consisted of more than 15  innovative assets, with two phase 3/registrational trials, seven phase 2 trials and eight phase 1 clinical trials. Its differentiated CD38 antibody felzartamab for MM third-line treatment is on track for BLA submission in Q42021. Other core clinical assets include Lemzoparlimab, a highly differentiated CD47, which made a global immuno-oncology strategic partnering deal with AbbVie in an aggregate amount of about 2 billion usd, Uliledlimab, a differentiated CD73 antibody, GM-CSF antibody, novel B7-H3 antibody, novel long-acting IL-7, differentiated long-acting growth hormone and the novel bi-specific antibodies such as L14B & CD4B driven by 2nd Wave Innovation. The Company also launched a discovery initiative to build a new portfolio of next generation of innovative drug candidates characterized as novel “super antibodies” enabled by transformative technologies such as an mRNA-based antibody, masked antibody, cell-penetrating antibody and AI-guided cytokine drugs etc.

The Company is on track to transition from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facilities and commercial capability. IMAB has established its global footprint in Shanghai (headquarter), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States.

For more information visit